-
RepRisk's AI-powered data drives transparency across JPX-Nikkei Indices
Trusted for its relevant coverage and unparalleled accuracy, RepRisk's AI-powered data, guided by human expertise, is now integrated across the JPX-Nikkei 400 and the JPX-Nikkei Mid and Small Cap indices. ZURICH, Oct. 15, 2025 -- Today, RepRisk, the world's most respected DaaS company for reputational risks and responsible business conduct, announced that its data is now used for the periodic review of eligible constituents of the JPX-Nikkei Index 400 and the JPX-Nikkei Mid and Small Cap Index. Powered by two decades of human-labeled data and a consistent, rules-based methodolo
- 황정호 기자
- 2025-10-15 07:00
-
AIを活用したRepRiskデータによって強化されるJPX日経インデックスの透明性
専門性の高いアナリストの知見とAIを効果的に活用するRepRiskのデータは、その広範なカバレッジと、卓越した正確性により、従来から広く信頼を得ておりますが、この度、JPX日経インデックス400、および、JPX日経中小型株指数の構築プロセスに統合されました。 スイス、チューリッヒ, 2025年10月15日 -- 本日、レピュテーションリスクと責任ある企業行動に関して最も信頼を得ているDaaS企業であるRepRiskは、自社のデータが、JPX日経インデックス400およびJPX日経中小型株指数の構成銘柄の定期入替に利用されることとなったことを発表致しました。これによって、東京証券取引所の上場会社において、責任ある企業行動が一層意識されることが期待されます。20年に亘り蓄積された人間によるラベル付けデータと、一貫性のあるルールに基づいた方法論を基盤とするRepRiskは、深い専門知識と知見を有するアナリストと、高度なAIを独自に組み合わせることで、グローバルのインベストメント・エコシステムとインデックス・プロバイダーに、企業行動リスクに関する信頼性の高い情報と洞察を提供し、意思決定をサポートしています。 JPX日経インデックス400と、JPX日経中小型株指数は、それぞれ2014年と2017年に算出が開始された株価指数であり、J
- 황정호 기자
- 2025-10-15 07:00
-
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
SHANGHAI, Oct. 15, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2025. As of Sep. 15, 2025, 74 patients with advanced solid tumor were enrolled and treated with 7MW3711 in the phase I/II study. Among 54 patients treated at 4.0 mg/kg or above and reaching tumor assessment, 19 partial responses (PRs) or complete resp
- 김갑성 기자
- 2025-10-15 00:00
-
Benchling Reveals the Next Chapter of R&D at Benchtalk 2025
Benchling AI debuts alongside major new capabilities for antibody discovery, automated data analysis, and development BOSTON, Oct. 14, 2025 -- Benchling today unveiled major new capabilities at Benchtalk, its annual customer conference. These new releases are designed to help biotech companies automate R&D workflows and bring the power of AI into scientists' everyday work. "At Benchling, we are on a mission to unlock the power of biotechnology. Advances in AI will help our customers get life-saving medicines to patients faster," said Sajith Wickramasekara,
- 김갑성 기자
- 2025-10-14 21:14
-
Co-PSMA trial achieves primary endpoint
SYDNEY, Oct. 14, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, has achieved its primary endpoint with a statistically significant higher number of prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions detected using 64Cu-
- 김갑성 기자
- 2025-10-14 21:03
-
HEX Launches Next-Generation Protective Gear with NBA Superstar Kyrie Irving
Irving joins HEX to showcase the brand's most advanced protective line yet, engineered with cutting-edge design to deliver lightweight, flexible, and breathable protection for the modern athlete. FOUNTAIN VALLEY, Calif., Oct. 14, 2025 -- HEX, the next-generation protective gear line from McDavid, today announced the launch of its most advanced performance apparel collection yet, engineered with cutting-edge design to deliver lightweight, flexible, and breathable protection for athletes who compete at the highest level. NBA superstar Kyrie Irving will play a leading role in show
- 황정호 기자
- 2025-10-14 21:01
-
IMG Expands iTravelInsured Choice with New Add-Ons and Specialized Plans
INDIANAPOLIS, Oct. 14, 2025 -- IMG (International Medical Group) has announced new optional coverage add-ons to its most popular travel insurance plan, iTravelInsured Choice, and the launch of two new products. Travelers now have the option to expand their iTravelInsured Choice coverage in several key areas through a variety of add-ons at an additional cost: Cancel For Any Reason (CFAR) & Interruption For Any Reason (IFAR) coverage Increased medical coverage Additional benefits and covered reasons specific to cruises Enhanced benefits to accommodate adventur
- 황정호 기자
- 2025-10-14 21:00
-
Securing Global Financial Transactions: ReconArt Achieves 70% Faster Compliance with Armor Defense and Oracle
DALLAS, Oct. 14, 2025 -- ReconArt, a leading provider of enterprise-class reconciliation and financial solutions, announced it has selected Armor Defense's Managed Detection and Response (MDR) services on Oracle Cloud Infrastructure (OCI) to secure its high-performance financial platform. In financial services, precision and resilience are non-negotiable. A single missed transaction or failed control can trigger financial loss, regulatory action, or lasting reputational damage. Sustaining this precision and resilience demands Armor's advanced defense - anticipating and neutrali
- 황정호 기자
- 2025-10-14 21:00
-
Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. All three studies highlight how Lunit's AI pathology solution, Lunit SCOPE IO®, can identify biomarkers that p
- 김갑성 기자
- 2025-10-14 21:00
-
bunq Accelerates Global Expansion with Premium Rewards Proposition Powered by Ascenda
Neobank elevates customer value and deepens engagement through Ascenda's global rewards network NEW YORK, Oct. 14, 2025 -- Ascenda, the loyalty company that powers growth for the world's leading financial institutions, today announced its new partnership with bunq, Europe's second-largest neobank. The collaboration elevates bunq's loyalty program, unlocking superior rewards that power its users' international lifestyle. bunq's skyrocketing trajectory - marked by its recent 20 million user milestone and plans for US expansion - is underpinned by a relentless
- 황정호 기자
- 2025-10-14 21:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-11-02_SUN
- Novo Tellus、Grand Venture Technologyとの変革的成長パートナーシップを完了 04:28
- Xinhua Silk Road: 중국 기업인들, 문화유산 계승과 혁신 모색 위한 회담 개최 03:36
- 로토부스트, 세계 최대 철강사 바오우와 협력해 천연가스 분해 기반 녹색 철강 산업화 추진 02:32
- iGarden Opens Pre-Sale for Swim Jet P Series -- The Perfect Swim Jet for Home Pool Fun 01:00
2025-11-01_SAT
- Manulife Hong Kong Supports 'Water Parade at Victoria Harbour' curated and organized by AllRightsReserved with Spectacular Drone Show Finale 23:49
- Youth Photography Featured at Japan's Prestigious Eastern International Fine Arts Exposition 22:53
- Xinhua Silk Road: Ziyuan County exhibits diverse agricultural products at international expo in Shenzhen 21:03
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 11월 02일 06시 00분